Curaleaf Acquires Remaining Stake in Germany’s Four 20 Pharma

STAMFORD, Conn. — Curaleaf Holdings Inc. acquired the 45-percent of Four 20 Pharma GmbH that Curaleaf did not already own. Four 20 Pharma is an EU-GMP and GDP licensed German producer and distributor of medical cannabis.

The acquisition of Four 20 Pharma expands Curaleaf’s vertically integrated global supply chain, from owned cultivation sources in Portugal and Canada through licensed distribution across Germany.

Since the initial acquisition in 2022, Curaleaf has launched the Four 20 brand in the United Kingdom and Poland and intends to continue expanding the brand across additional international markets.

Related Articles:

Curaleaf Global Cannabis Playbook Emerges Amid U.S. Uncertainty The Pre-Roll Market in 2026: Growth, Pressure, and Operational Reality Jeff Wu on Manufacturing, Compliance, and Culture